Shanghai-based minimally invasive surgical robot developer, Ronovo Surgical, has reportedly raised close to RMB 200 million (USD 27.5 million) in a pre-Series B+ financing round. The round was led by NRL Capital, with contributions from Kington Capital, Lilly Asia Ventures, Vivo Capital, Matrix Partners, GGV Capital, and LongRiver Investments. The funds raised will be directed towards product clinical trial filings, research and development costs, as well as the implementation and brand promotion of modular surgical robots.
Investment in Modular Surgical Robotics
Ronovo Surgical boasts the distinction of developing China’s first split modular surgical robot, which is now entering human trials. The product offers a modular, agile, and configurable solution that is anticipated to reduce the economic burden associated with robotic-assisted surgery (RAS). This development is a significant step towards making advanced surgical technologies more accessible and affordable.
Implications for the Surgical Robotics Market
The investment in Ronovo Surgical underscores the growing interest in modular surgical robotics, which have the potential to transform the field of minimally invasive surgery. By lowering costs and improving the efficiency of surgical procedures, Ronovo’s modular robots could become a game-changer in the surgical robotics market.-Fineline Info & Tech
